click on circles to display study description...

Chaccour, 2020 NCT04390022

ivermectin (n=12) vs. placebo (n=12)

randomized controlled trial

ivermectin
400 mcg/kg, single dose

placebo

COVID 19 outpatients

double bliind

1 center, Spain

Lopez-Medina, 2021 NCT04405843

ivermectin (n=200) vs. placebo (n=200)

randomized controlled trial

Ivermectin
300 µg/kg of body weight per day of oral ivermectin in solution, for 5 days.

Placebo
300 µg/kg of body weight per day of oral placebo for 5 days.

Placebo was a solution with similar organoleptic properties to ivermectin. Bottles of ivermectinand placebo were identical throughout the study period toguarantee double-blinding.

COVID 19 outpatients

Adult subjects over 18 years of age with SARS CoV2 / COVID 19 disease confirmed by antigen detection tests authorized by INVIMA or by RT-PCR in any of the laboratories that report to the Departmental Health Secretary, approved for the diagnosis of COVID-19 by the National Institute of Health. Onset of SARS CoV2 / COVID 19 illness 7 days ago or less, subjects with mild disease, informed consent signature.

Double-blind.

Single site in Cali, Colombia.

TOGETHER (ivermectine), 2022 NCT04727424

ivermectin (n=679) vs. placebo (n=679)

randomized controlled trial

Ivermectin 400 mcg/kg up to 90kg weight every 24 hours for 3 days

placebo

COVID 19 outpatients

double-blind

12 public health clinics in Brazil

adaptive platform trial

IVERCORCOVID19 (Vallejos), 2020 NCT04529525

ivermectin (n=250) vs. placebo (n=251)

randomized controlled trial

ivermectin
24 to 48 mg (depends on the weight of the patient) at day 1 and day 2

placebo

COVID 19 outpatients

double-blind

1 center, Argentina

ACTIV 6 ivermectin, 2022 NCT04885530

ivermectin (n=817) vs. placebo (n=774)

randomized controlled trial

ivermectin 400 mcg/kg daily for 3 days

placebo

COVID 19 outpatients

non-hospitalized adults age >=30 years with confirmed COVID-19, experiencing 2 or more symptoms of acute infection for <=7 days

double-blind

COVID-OUT (ivermectin), 2022 NCT04510194

ivermectin (n=410) vs. placebo (n=398)

randomized controlled trial

ivermectin at a dose of 390 to 470 μg per kilogram per day for 3 days

placebo

COVID 19 outpatients

double-blind

US, 6 centres

2-by-3 factorial design (metformin, ivermectin, and fluvoxamine)

ACTIV-6 (ivermectine), 2023 NCT04885530

ivermectin (n=602) vs. placebo (n=604)

randomized controlled trial

ivermectin, with a maximum targeted dose of 600 μg/kg for 6 days

placebo

COVID 19 outpatients

double-blind

93 sites in the US